|
ESLA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -0.98 %
net loss increased from $0 millions, to $-1 millions in III. Quarter 2024,
• More on ESLA's Growth
|
|
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 17.18 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.96.
• More on ESLA's Valuation
|
|
|
|
|
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 17.18 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.96.
Price to Book Ratio is at 4.56 lower than Industry Avg. of 1046.11. and higher than S&P 500 Avg. of 0
• More on ESLA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com